MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lun…
$3.90+3.72%
报价 2026-11-06
市值
$1.25B
EV
$1.52B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -37.2%
$2.28$6.21
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MNKDMannKind Corporation | $1.25B | +3.7% | +28.5% | 75.7% | – | 49.6x | – | |
| ABCLAbCellera Biologics Inc. | $3.85B | +6.7% | – | 75% | – | – | – | |
| CLDXCelldex Therapeutics, Inc. | $2.35B | +5.7% | -11.1% | 100% | – | – | – | |
| AUPHAurinia Pharmaceuticals Inc. | $2.21B | +1.5% | – | 88.5% | 6.8x | 13.6x | – | |
| BHVNBiohaven Ltd. | $2.19B | +4.2% | +55466.7% | 0% | – | – | – | |
| VERAVera Therapeutics, Inc. | $2.15B | -1.2% | – | 0% | – | – | – | |
| HRMYHarmony Biosciences Holdings, Inc. | $1.93B | +2.0% | +17.2% | 77.2% | 10.0x | 4.3x | 5.5x | |
| IMCRImmunocore Holdings plc | $1.6B | +9.1% | – | 98.7% | – | – | – | |
| NUVBNuvation Bio Inc. | $1.46B | -0.7% | +245.0% | 86.6% | – | – | – | |
| 同行中位数 | – | – | +131.1% | 81.9% | 8.4x | 8.9x | 5.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
电话会纪要摘要
暂无纪要摘要。